Probiotics for the prevention of gestational diabetes mellitus in overweight and obese women: findings from the SPRING double-blind randomized controlled trial
Callaway, Leonie K., McIntyre, H. David, Barrett, Helen L., Foxcroft, Katie, Tremellen, Anne, Lingwood, Barbara E., Tobin, Jacinta M., Wilkinson, Shelley, Kothari, Alka, Morrison, Mark, O'Rourke, Peter, Pelecanos, Anita, and Nitert, Marloes Dekker (2019) Probiotics for the prevention of gestational diabetes mellitus in overweight and obese women: findings from the SPRING double-blind randomized controlled trial. Diabetes Care, 42 (3). pp. 364-371.
PDF (Published Version)
- Published Version
Restricted to Repository staff only |
Abstract
OBJECTIVE: Given the role of gut microbiota in regulating metabolism, probiotics administered during pregnancy might prevent gestational diabetes mellitus (GDM). This question has not previously been studied in high-risk overweight and obese pregnant women. We aimed to determine whether probiotics (Lactobacillus rhamnosus and Bifidobacterium animalis subspecies lactis) administered from the second trimester in overweight and obese women prevent GDM as assessed by an oral glucose tolerance test (OGTT) at 28 weeks' gestation. Secondary outcomes included maternal and neonatal complications, maternal blood pressure and BMI, and infant body composition.
RESEARCH DESIGN AND METHODS: This was a double-blind randomized controlled trial of probiotic versus placebo in overweight and obese pregnant women in Brisbane, Australia.
RESULTS: The study was completed in 411 women. GDM occurred in 12.3% (25 of 204) in the placebo arm and 18.4% (38 of 207) in the probiotics arm (P = 0.10). At OGTT, mean fasting glucose was higher in women randomized to probiotics (79.3 mg/dL) compared with placebo (77.5 mg/dL) (P = 0.049). One- and two-hour glucose measures were similar. Preeclampsia occurred in 9.2% of women randomized to probiotics compared with 4.9% in the placebo arm (P = 0.09). Excessive weight gain occurred in 32.5% of women in the probiotics arm (55 of 169) compared with 46% in the placebo arm (81 of 176) (P = 0.01). Rates of small for gestational age (<10th percentile) were 2.4% in the probiotics arm (5 of 205) and 6.5% in the placebo arm (13 of 199) (P = 0.042). There were no differences in other secondary outcomes.
CONCLUSIONS: The probiotics used in this study did not prevent GDM in overweight and obese pregnant women.
Item ID: | 57427 |
---|---|
Item Type: | Article (Research - C1) |
ISSN: | 1935-5548 |
Copyright Information: | © 2019 by the American Diabetes Association. |
Funders: | National Health and Medical Research Council (NHMRC), Royal Brisbane and Women's Hospital Foundation |
Projects and Grants: | NHMRC APP1028575 |
Date Deposited: | 13 Mar 2019 07:50 |
FoR Codes: | 32 BIOMEDICAL AND CLINICAL SCIENCES > 3202 Clinical sciences > 320208 Endocrinology @ 50% 32 BIOMEDICAL AND CLINICAL SCIENCES > 3215 Reproductive medicine > 321502 Obstetrics and gynaecology @ 50% |
SEO Codes: | 92 HEALTH > 9205 Specific Population Health (excl. Indigenous Health) > 920507 Womens Health @ 50% 92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920104 Diabetes @ 50% |
More Statistics |